Description of the patient cohort and clinical parameters
| . | Controls . | ET . | PMF . | PV . | Post-MPN sAML . |
|---|---|---|---|---|---|
| WHO classification (2016) | |||||
| n (%) | 15 (11.7%) | 32 (25.0%) | 55 (43.0%) | 17 (13.3%) | 9 (7.0%) |
| Demographics | |||||
| Sex, n | 7 (f), 8 (m) | 21 (f), 11 (m) | 29 (f), 26 (m) | 9 (f), 8 (m) | 4 (f), 5 (m) |
| Age, mean ± SD, y | 37.4 ± 11.2 | 67.2 ± 11.8 | 65.5 ± 12.8 | 64.4 ± 11.0 | 74.3 ± 8.2 |
| Genotype | |||||
| Driver mutation status, n | NA | 17 JAK2-V617F 11 CALR (type 1 & 2) 4 triple-negative | 26 JAK2-V617F 29 CALR (type 1 & 2) | 16 JAK2-V617F 1 JAK2 exon 12 | 8 JAK2-V617F 1 MPL-W515A |
| Blood parameters at diagnosis | |||||
| Hemoglobin level, g/dL | NA | 14.0 ± 1.3 | 12.6 ± 1.8 | NA | NA |
| White blood cell count, g/dL | NA | 9.4 ± 2.8 | 9.9 ± 5.3 | NA | NA |
| Platelet count, ×109/L | NA | 853.6 ± 294.1 | 762.7 ± 444.6 | NA | NA |
| Outcome | |||||
| Overall survival, mean ± SD, mo | NA | 185 ± 77 | 158 ± 87 | 145 ± 86 | NA |
| . | Controls . | ET . | PMF . | PV . | Post-MPN sAML . |
|---|---|---|---|---|---|
| WHO classification (2016) | |||||
| n (%) | 15 (11.7%) | 32 (25.0%) | 55 (43.0%) | 17 (13.3%) | 9 (7.0%) |
| Demographics | |||||
| Sex, n | 7 (f), 8 (m) | 21 (f), 11 (m) | 29 (f), 26 (m) | 9 (f), 8 (m) | 4 (f), 5 (m) |
| Age, mean ± SD, y | 37.4 ± 11.2 | 67.2 ± 11.8 | 65.5 ± 12.8 | 64.4 ± 11.0 | 74.3 ± 8.2 |
| Genotype | |||||
| Driver mutation status, n | NA | 17 JAK2-V617F 11 CALR (type 1 & 2) 4 triple-negative | 26 JAK2-V617F 29 CALR (type 1 & 2) | 16 JAK2-V617F 1 JAK2 exon 12 | 8 JAK2-V617F 1 MPL-W515A |
| Blood parameters at diagnosis | |||||
| Hemoglobin level, g/dL | NA | 14.0 ± 1.3 | 12.6 ± 1.8 | NA | NA |
| White blood cell count, g/dL | NA | 9.4 ± 2.8 | 9.9 ± 5.3 | NA | NA |
| Platelet count, ×109/L | NA | 853.6 ± 294.1 | 762.7 ± 444.6 | NA | NA |
| Outcome | |||||
| Overall survival, mean ± SD, mo | NA | 185 ± 77 | 158 ± 87 | 145 ± 86 | NA |
WHO, World Health Organization.
PV patients were all JAK2 positive (16 JAK2-V617F, 1 JAK2 exon 12), 26 PMF patients were JAK2-V617F positive and 29 were CALR positive (17 type 1 or type 1-like, 12 type 2 or type 2-like), 17 ET patients carried JAK2 mutations and 11 carried CALR mutations (4 type 1, 7 type 2 or type 2-like), and 4 patients were triple-negative cases. All post-MPN sAML patients were JAK2-V617F positive, with the exception of 1 patient with an MPL (W515A) mutation (Figure 1A; supplemental Table 1).